Maureen McEvoy

home / authors / maureen-mcevoy

Articles

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

Sheng Chow;Meredith Shamamian;Susan Laura Jao;Andreina Giron;Jessica Lin;Fardeen Bhimani;Eleni Kohilakis;Caroline Oska;Jana Fox;Sheldon Feldman;Maureen McEvoy
May 14th 2025
64 A Prospective Study to Accurately Define the Nipple-Ward Margins in Patients Undergoing Lumpectomy for Breast Cancer

64 A Prospective Study to Accurately Define the Nipple-Ward Margins in Patients Undergoing Lumpectomy for Breast Cancer

Susan Laura Jao;Fardeen Bhimani;Arianna Cavalli;Bryan Harmon;Maureen McEvoy;Ethan Ravetch;Michelle Sheckley;Anjuli Gupta;Sheldon Feldman
May 13th 2025
68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population

68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population

Arianna Cavalli;Susan Laura Jao;Skylar Harbour;Melissa Rony;Sheldon Feldman;Maureen McEvoy
May 10th 2025
40 Ethnic Disparities in Complication Rates and Outcomes of Nipple-Sparing Mastectomy: A Comprehensive Analysis

40 Ethnic Disparities in Complication Rates and Outcomes of Nipple-Sparing Mastectomy: A Comprehensive Analysis

Arianna Cavalli;Fardeen Bhimani;Lesley G. Coe;Liane N. Obaid;Anjuli Gupta;Jessica Pastoriza;Sheldon Feldman;Maureen McEvoy
June 8th 2024
49 The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study

49 The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study

Liane N. Obaid;Janice S. Zhang;Grace Y. Lee;Fardeen Bhimani;Lesley G. Coe;Arianna Cavalli;Anjuli Gupta;Jessica Pastoriza;Sheldon Feldman;Maureen McEvoy
May 22nd 2024
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer

56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer

Lesley G. Coe;Fardeen Bhimani;Liane N. Obaid;Arianna Cavalli;Anjuli Gupta;Jessica Pastoriza;Sheldon Feldman;Maureen McEvoy
May 14th 2024

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Data from the phase 3 CheckMate 77T trial support the CHMP’s opinion on approving the perioperative nivolumab regimen for those with resectable NSCLC.
Published: April 2nd 2025 | Updated: May 20th 2025
EU’s CHMP Recommends Approving Perioperative Nivolumab Combo in NSCLC
OSZAR »